Neuralstem, Inc. Form 10-Q Summary
Source discrepancy: The provided filing is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarter and nine months ended September 30, 2011; interim financial statements are unaudited.
Business Context and Reporting Period
Neuralstem is a development-stage biotechnology company focused on human neural stem-cell therapies and small-molecule compounds for central nervous system disorders. Its lead programs included Phase I trials for amyotrophic lateral sclerosis and NSI-189 for major depressive disorder. The company had 14 full-time employees and two full-time independent contractors at September 30, 2011.
The company reported $103,417 of revenue for the three and nine months ended September 30, 2011, generated from services as principal subcontractor under a Department of Defense contract awarded to Loma Linda University. It reported no product sales revenue.
Financial Condition and Key Metrics
| Metric | Three Months Ended September 30, 2011 | Nine Months Ended September 30, 2011 |
|---|---|---|
| Revenue | $103,417 | $103,417 |
| Research and development expense | $2,124,204 | $5,948,603 |
| General and administrative expense | $1,137,995 | $4,433,703 |
| Total operating expenses | $3,326,484 | $10,531,854 |
| Operating loss | $(3,223,067) | $(10,428,437) |
| Net loss | $(3,211,604) | $(9,962,131) |
| Loss per share | $(0.07) | $(0.21) |
| Net cash used in operating activities | Not separately provided | $(6,314,028) |
Operating and net margins were deeply negative because revenue was minimal relative to research and development spending; revenue-based margins are not meaningful for this development-stage company. Cash and cash equivalents were $4.20 million at September 30, 2011, compared with $9.26 million at December 31, 2010 and $11.59 million at September 30, 2010. Total current assets were $4.85 million and current liabilities were $1.99 million, producing working capital of approximately $2.86 million.
Total liabilities were $1.99 million. The filing does not disclose conventional interest-bearing debt at September 30, 2011. The fair value of warrant obligations was zero after the remaining derivative warrants were exercised or expired. Stockholders’ equity was $3.90 million, and accumulated deficit was $95.92 million.
Investing cash outflows were $420,060, primarily for intangible assets and property and equipment. Financing cash inflows were $1.67 million from warrant exercises. The company reported an approximate monthly cash burn rate of $800,000 during the first three quarters of 2011.
Material Changes Versus Prior Comparable Period
- Revenue increased from zero to $103,417 for both the quarter and year-to-date period, entirely from the Department of Defense subcontract.
- Third-quarter operating expenses decreased 15% to $3.33 million, mainly because general and administrative expense declined 36% and stock-based compensation was lower.
- Nine-month operating expenses declined 10% to $10.53 million, reflecting lower non-cash stock-based compensation in both research and development and general and administrative expenses.
- Nine-month net loss improved to $9.96 million from $15.65 million, principally because 2010 included substantial warrant issuance, modification, and fair-value expense.
- Cash used in operations decreased 13% to $6.31 million, while investing cash use increased 103% to $420,060.
- Financing proceeds fell 90% from $16.72 million to $1.67 million because the significant June 2010 financing had no comparable 2011 transaction.
- Shares outstanding increased to 48.68 million from 46.90 million at December 31, 2010, reflecting warrant exercises and equity compensation or service arrangements.
Guidance, Outlook, Risks, and Unusual Items
- Management expected existing cash to fund current operations and clinical and preclinical work into the first quarter of 2012, but stated that substantial additional capital would be required thereafter.
- The company did not expect to be profitable in the next several years and anticipated additional operating losses.
- The ALS Phase I trial had treated 12 patients; the FDA permitted the final six patients to be treated in the cervical region, with the next patient expected in December 2011.
- The chronic spinal cord injury IND remained on clinical hold and had not been approved. The company planned to revisit the program after additional human and animal safety data.
- The Phase Ia NSI-189 trial was completed in October 2011, and management expected to begin the Phase Ib portion during the fourth quarter of 2011.
- The company recognized a $250,000 litigation settlement from ReNeuron. Future milestone payments under the settlement were uncertain.
- Remaining warrant obligations were eliminated during the first quarter of 2011, producing a $161,809 gain from changes in fair value for the nine-month period.
- Material risks included dependence on external financing, potential dilution, uncertain clinical and regulatory outcomes, lack of commercial product revenue, reliance on third-party manufacturers and contractors, intellectual-property litigation, and competition from better-funded companies.
- Neuralstem and StemCells, Inc. remained involved in patent-related litigation. The filing stated that the timing and outcome could not be determined.
- Management concluded that disclosure controls and procedures were effective and reported no material changes to internal control over financial reporting during the quarter.
Investor Verification Checklist
- Confirm the issuer identity: the supplied filing is Neuralstem, Inc., despite the request metadata identifying Palisade Bio, Inc.
- Verify the company’s cash runway against its approximately $800,000 monthly burn rate and the stated funding horizon into the first quarter of 2012.
- Review subsequent financing activity, share issuance, warrant exercises, and dilution following September 30, 2011.
- Track FDA status and clinical results for the ALS, chronic spinal cord injury, and NSI-189 programs.
- Assess the Department of Defense subcontract’s milestones, remaining potential funding, and revenue-recognition terms.
- Review the status and potential financial or intellectual-property consequences of the StemCells litigation.
- Reconcile non-cash stock-based compensation and warrant-related gains and expenses when evaluating underlying cash burn and operating performance.